Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Status:
Recruiting
Trial end date:
2025-04-29
Target enrollment:
Participant gender:
Summary
This study will determine the pharmacodynamically-active dose of gevokizumab and the
tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of
care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic
gastroesophageal cancer and metastatic renal cell carcinoma.